BR9710586A - Composição para administração entérica, processos para intensificar a resistência fìsica de um mamìfmamìfero, para o tratamento de osteoporose em um ser humano, para o tratamento de catabiolismo em um ser humano, causado pela aidas ou pelo câncer e para melhorar os efeitos do exercìcio fìsico, e, composição proteica anabólica. - Google Patents

Composição para administração entérica, processos para intensificar a resistência fìsica de um mamìfmamìfero, para o tratamento de osteoporose em um ser humano, para o tratamento de catabiolismo em um ser humano, causado pela aidas ou pelo câncer e para melhorar os efeitos do exercìcio fìsico, e, composição proteica anabólica.

Info

Publication number
BR9710586A
BR9710586A BR9710586A BR9710586A BR9710586A BR 9710586 A BR9710586 A BR 9710586A BR 9710586 A BR9710586 A BR 9710586A BR 9710586 A BR9710586 A BR 9710586A BR 9710586 A BR9710586 A BR 9710586A
Authority
BR
Brazil
Prior art keywords
composition
human
treatment
mammal
pyruvate
Prior art date
Application number
BR9710586A
Other languages
English (en)
Other versions
BR9710586C1 (pt
Inventor
Paxton K Beale
Donald O Nickey
Original Assignee
Paxton K Beale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Paxton K Beale filed Critical Paxton K Beale
Publication of BR9710586C1 publication Critical patent/BR9710586C1/pt
Publication of BR9710586A publication Critical patent/BR9710586A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

RA PERCENTUAL DO CORPO EM UM MAMìFERO, COMPOSIçãO R A GORDURA PERCENTUAL DO CORPO EM UM MAMìFERO, PReendente verificação de que o uso de piruvato em formulações entéricas, em combinação com uma composição protéica anabólica, produz um efeito sinérgico no aumento da massa corporal magra ou do tecido muscular de um mamífero que as consome. A presenteo para intensificar a concentração protéica ou a massa muscular de uma mamífero, e a um processo para intensificar a concentração protéica ou a massa muscular de um mamífero. Mas especificamente, o presente certificado de adição diz respeito a uma composição que compreende piruvato e/ou derivados de piruvato e uma composição protéica anabólica. O processo da presente invenção compreende a ministraoncentração protéica ou massa muscular, de uma composição compreendendo piruvato e uma composição protéica anabólica. O piruvato/composição protéica anabólica pode tomar a forma de pós, líquidos, pílulas, cápsulas, tabletes, aditivos alimentares, açúcares ou confeitos.
BR9710586A 1996-07-26 1997-07-25 Composição para administração entérica, processos para intensificar a resistência fìsica de um mamìfmamìfero, para o tratamento de osteoporose em um ser humano, para o tratamento de catabiolismo em um ser humano, causado pela aidas ou pelo câncer e para melhorar os efeitos do exercìcio fìsico, e, composição proteica anabólica. BR9710586A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/686,819 US5716926A (en) 1996-07-26 1996-07-26 Composition of pyruvate and protein and method for increasing protein concentration in a mammal
PCT/US1997/013162 WO1998004254A1 (en) 1996-07-26 1997-07-25 Composition of pyruvate and protein and method for increasing protein concentration in a mammal

Publications (2)

Publication Number Publication Date
BR9710586C1 BR9710586C1 (pt) 2000-03-21
BR9710586A true BR9710586A (pt) 2000-03-21

Family

ID=24757898

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9710586A BR9710586A (pt) 1996-07-26 1997-07-25 Composição para administração entérica, processos para intensificar a resistência fìsica de um mamìfmamìfero, para o tratamento de osteoporose em um ser humano, para o tratamento de catabiolismo em um ser humano, causado pela aidas ou pelo câncer e para melhorar os efeitos do exercìcio fìsico, e, composição proteica anabólica.

Country Status (6)

Country Link
US (2) US5716926A (pt)
EP (1) EP0914109A1 (pt)
BR (1) BR9710586A (pt)
CA (1) CA2261708A1 (pt)
CZ (1) CZ24999A3 (pt)
WO (1) WO1998004254A1 (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576287A (en) * 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
US6221836B1 (en) * 1996-07-26 2001-04-24 Paxton King Beale Composition of pyruvate and anabolic protein and method for increasing fat loss in a mammal
US6008252A (en) * 1996-07-26 1999-12-28 Beale; Paxton K. Method for increasing muscle mass in a mammal
TW404833B (en) * 1997-07-11 2000-09-11 Sueddeutsche Kalkstickstoff A method of producing calcium pyruvates
DE19729786A1 (de) * 1997-07-11 1999-01-14 Sueddeutsche Kalkstickstoff Verfahren zur Herstellung von Calciumpyruvaten
EP1100488B1 (en) * 1998-07-28 2003-04-23 SYNTHES AG Chur Use of creatine compounds for treatment of bone or cartilage cells and tissues
DE19836450A1 (de) * 1998-08-12 2000-02-17 Sueddeutsche Kalkstickstoff Stabile, Brenztraubensäure (Salze) enthaltende Formulierung für die Tierernährung
GB9923048D0 (en) * 1999-09-29 1999-12-01 Nestle Sa Composition comprising casein protein and whey protein
US20070037777A1 (en) * 2005-08-12 2007-02-15 Immunopath Profile, Inc. Lipid-containing compositions and methods of using them
US6277842B1 (en) 2000-10-17 2001-08-21 James Alexander Carthron Dietary supplemental method for fat and weight reduction
ITMI20010204A1 (it) * 2001-02-02 2002-08-02 Hunza Di Marazzita Maria Carme Specialita' terapeutiche dotate di attivita' antiossidante ed in grado di controllare l'eccesso del peso corporeo
US6864242B2 (en) * 2001-03-05 2005-03-08 Stephen P. Ernest Enteral formulation
US6479683B1 (en) 2001-03-06 2002-11-12 Ag Processing Inc Process for conjugating fatty acid esters
JPWO2003011056A1 (ja) * 2001-07-31 2004-11-18 味の素株式会社 疲労回復用食品組成物
US7179617B2 (en) * 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7745489B2 (en) * 2002-03-07 2010-06-29 The Regents Of The University Of California Compositions and methods for inhibition of phospholipase A2 mediated inflammation
BRPI0414505A (pt) * 2003-09-19 2006-11-07 Nutricia Nv uso de carboidratos solúveis em água digerìveis e de um ou mais promotores da glutationa, e, composição
US20060025475A1 (en) * 2004-07-29 2006-02-02 Stanley Antosh Use of methyl pyruvate for the purpose of increasing muscle energy production.
JP4923236B2 (ja) * 2005-03-09 2012-04-25 国立大学法人金沢大学 骨密度向上剤、抗骨粗鬆症薬および抗骨粗鬆症食品
ATE508745T1 (de) * 2005-11-30 2011-05-15 Novartis Pharma Gmbh Kombination umfassend mindestens eine aminosäure und einen pkr-inhibitor zur verwendung in der behandlung von muskelschwund
US7982066B2 (en) * 2005-12-09 2011-07-19 Novalife, Inc. High protein supplement
CN101472613A (zh) * 2006-04-12 2009-07-01 R·L·亚历山大 包含丙酮酸烷基酯的组合物及其应用
US20070286909A1 (en) * 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
AU2007358961A1 (en) * 2007-09-11 2009-03-19 Northern Innovations And Formulations Corp. Composition and method for increasing the anabolic state of muscle cells
US7645794B2 (en) 2007-09-11 2010-01-12 Multi Formulations Ltd. Composition and method for increasing the anabolic state of muscle cells
US7820618B2 (en) * 2007-10-04 2010-10-26 Northern Innovations and Formulations Energy status of an individual by enhanced usage of an endogenous fuel source
WO2009043136A1 (en) * 2007-10-04 2009-04-09 Multi Formulations Ltd. Improving the energy status of an individual by enhanced usage of an endogenous fuel source
US8173181B2 (en) * 2009-11-09 2012-05-08 Bio-Engineered Supplements & Nutrition, Inc. Method and composition for improved anabolism
BE1019709A3 (fr) * 2010-12-22 2012-10-02 Calxx Laboratoires S A Produit alimentaire organo-mineral et procede de preparation.
EP2742938B1 (en) * 2011-08-08 2018-05-09 Ajinomoto Co., Inc. Amino-acid-containing composition for enhancing recovery from muscle fatigue
US9820504B2 (en) 2013-03-08 2017-11-21 Axiom Foods, Inc. Rice protein supplement and methods of use thereof
EP2996487B1 (en) 2013-03-08 2019-12-11 Axiom Foods Inc. Rice protein supplements
EP3057451A4 (en) * 2013-10-16 2017-06-21 Ensisheim Partners LLC Protein-specific formulations
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
CN110868870A (zh) 2017-05-12 2020-03-06 艾斯姆食品公司 大米产物及制备它们的系统和方法
JP7266581B2 (ja) * 2017-08-14 2023-04-28 アクセラ・ヘルス・インコーポレイテッド 肝疾患の治療のためのアミノ酸組成物
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US11458114B2 (en) * 2020-05-19 2022-10-04 North Cell Pharmaceuticals, Inc. Methods and compositions for enhancing synthesis secretion and transport of collagen to increase wound strength

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4042688A (en) * 1975-11-24 1977-08-16 Control Drug, Inc. Method of providing high-protein nutrition by the oral administration of a predigested protein composition
US4025650A (en) * 1975-11-24 1977-05-24 Control Drug, Inc. Method and composition for preventing nutritional deficiency
US4645764A (en) * 1981-04-01 1987-02-24 Montefiore Hospital Method for preventing body fat deposition in animals
US4351835A (en) * 1981-04-01 1982-09-28 Montefiore Hospital Method for preventing body fat deposition in mammals
US4812479A (en) * 1981-04-01 1989-03-14 The Montefiore Hospital Society Of Western Pennsylvania, Inc. Method for preventing body fat deposition in mammals
US4548937A (en) * 1981-04-01 1985-10-22 Montefiore Hospital Method for preventing body fat deposition in mammals
US4415576A (en) * 1981-04-01 1983-11-15 Montefiore Hospital Method for preventing body fat deposition in mammals
ATE22655T1 (de) * 1982-11-10 1986-10-15 Laevosan Gmbh & Co Kg Infusionsloesungen zur herztherapie.
US4687782A (en) * 1984-12-10 1987-08-18 Nutri-Fuels Systems, Inc. Nutritional composition for enhancing skeletal muscle adaptation to exercise training
US5719119A (en) * 1985-12-18 1998-02-17 British Technology Group, Ltd. Parenteral nutrition therapy with amino acids
US4871550A (en) * 1986-09-05 1989-10-03 Millman Phillip L Nutrient composition for athletes and method of making and using the same
US4988515A (en) * 1988-01-28 1991-01-29 The Regents Of The Univ. Of Calif. Cardioplegic solution
US4981687A (en) * 1988-07-29 1991-01-01 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US5089477A (en) * 1988-07-29 1992-02-18 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US5236712A (en) * 1988-07-29 1993-08-17 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US5238684A (en) * 1988-07-29 1993-08-24 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US5147650A (en) * 1988-07-29 1992-09-15 University Of Florida Compositions and methods for achieving improved physiological response to exercise
US4874790A (en) * 1988-08-15 1989-10-17 Montefiore Hospital Association Of Western Pennsylvania Method for improving the glucose metabolism of an animal having diabetic tendencies
US5143842A (en) * 1988-11-01 1992-09-01 The University Of Colorado Foundation, Inc. Media for normal human muscle satellite cells
SE462463B (sv) * 1988-12-02 1990-07-02 Decken Alexandra V D Livs- och fodermedel innehaallande ketosyror
US5026721A (en) * 1989-06-05 1991-06-25 Dudrick Stanley J Amino acid nutritional supplement and regimen for enhancing physical performance through sound nutrition
DE3940052A1 (de) * 1989-12-04 1991-06-06 Nephro Medica Pharma Dialysier- und spuelloesung zur intraperitonealen verabreichung
US5087472A (en) * 1990-01-30 1992-02-11 Iowa State University Research Foundation, Inc. Feed compositions for domestics animals containing hydroxymethylbutyrate
US5028440A (en) * 1990-01-30 1991-07-02 Iowa State University Research Foundation, Inc. Method of raising meat producing animals to increase lean tissue development
US5134162A (en) * 1990-12-24 1992-07-28 The Montefiore Hospital Association Of Western Pennsylvania Method for lowering high blood cholesterol levels in hyperlipidemic animals and confections as the ingestion medium
US5294641A (en) * 1991-11-27 1994-03-15 Montefiore - University Hospital Method for treating a medical patient for cardiac trauma
US5221668A (en) * 1992-02-26 1993-06-22 Abbott Laboratories Nutritional product for trauma and surgery patients
US5508308A (en) * 1992-04-16 1996-04-16 Abbott Laboratories Use of pyruvylglycine to treat ischemia/reperfusion injury following myocardial infarction
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
US5430066A (en) * 1992-04-29 1995-07-04 Wisconsin Alumni Research Foundation Methods for preventing weight loss, reduction in weight gain, and anorexia due to immune stimulation
US5428072A (en) * 1992-04-29 1995-06-27 Wisconsin Alumni Research Foundation Method of increasing the efficiency of feed conversion in animals
NZ256300A (en) * 1992-09-16 1997-06-24 Univ Iowa State Res Found Inc Administration of beta-hydroxy-beta-methyl butyric acid, or its convertible forms, to lower cholesterol levels
US5294606A (en) * 1992-11-24 1994-03-15 Reliv' International Inc. Isotonic energy composition and method to use same
US5348979A (en) * 1992-12-23 1994-09-20 Iowa State University Research Foundation Inc. Method of promoting nitrogen retention in humans
US5536751A (en) * 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof
US5480909A (en) * 1994-08-08 1996-01-02 University Of Pittsburgh Medical Center Method for inhibiting generation of free-radicals

Also Published As

Publication number Publication date
BR9710586C1 (pt) 2000-03-21
US5889040A (en) 1999-03-30
CZ24999A3 (cs) 1999-06-16
WO1998004254A1 (en) 1998-02-05
EP0914109A1 (en) 1999-05-12
US5716926A (en) 1998-02-10
CA2261708A1 (en) 1998-02-05

Similar Documents

Publication Publication Date Title
BR9710586A (pt) Composição para administração entérica, processos para intensificar a resistência fìsica de um mamìfmamìfero, para o tratamento de osteoporose em um ser humano, para o tratamento de catabiolismo em um ser humano, causado pela aidas ou pelo câncer e para melhorar os efeitos do exercìcio fìsico, e, composição proteica anabólica.
Legault et al. The influence of oral L-glutamine supplementation on muscle strength recovery and soreness following unilateral knee extension eccentric exercise
TARNOPOLSKY et al. Creatine-dextrose and protein-dextrose induce similar strength gains during training
Liao et al. Prospective views for whey protein and/or resistance training against age-related sarcopenia
Schachter et al. Treatment of oligospermia with the amino acid arginine
De Rui et al. Dietary strategies for mitigating osteosarcopenia in older adults: a narrative review
BR9710585A (pt) Composição para administração enteral, processo para melhorar a resistência fìsica ou desempenho atlético de um mamìfero, para aumentar a concentração de proteìna, massa corporal sem gordura ou massa muscular em um mamìfero, para diminuir a deposição de gordura corporal para uma dada ingestão calórica e aumentar a perda de gordura corporal em um mamìfero, para tratar os efeitos catabólicos de doença em um mamìfero, para aperfeiçoar a resistência fìsica ou o desempenho atléticode um mamìfero, e, para aumentar a massa de um corpo de carne magra de um mamìfero e diminuir a deposição de gordura
BR0212985A (pt) Uso de pyy ou de um agonista do mesmo na preparação de medicamentos para tratamento de distúrbios associados com excesso de peso
Esposito et al. A medical food formulation of Griffonia simplicifolia/magnesium for childhood periodic syndrome therapy: An open-label study on motion sickness
CN107348522A (zh) 一种改善老年人运动系统功能的营养组合物及其制备方法
Di Girolamo et al. Contraction and nutrition interaction promotes anabolism in cachectic muscle
PT1065947E (pt) Metodo de administracao de glutamina
BR112022014911A2 (pt) Composição de saúde articular e uso da mesma em mamíferos saudáveis
RU2679802C2 (ru) Действующее вещество для лечения саркопении
Durmus et al. The efficiency of electromagnetic field treatment in Complex Regional Pain Syndrome Type I
BR9813856A (pt) Processos para o tratamento de uma paciente que sofre de sìndrome pré-menstrual, depressão, anemia, enxaquecas ou distúrbios alimentares e para aumentar o nìvel de serotonin em um ser humano com nìvel reduzido do mesmo no fluxo sanguìneo e composição
Serafini et al. Nutritional approach to sarcopenia
AU2022201367A1 (en) Compositions and methods of use of ß-hydroxy-ß-methylbutyrate (HMB) for enhancing recovery from soft tissue trauma
SE9201584D0 (sv) Use of alpha-ketoglutarate
Landers-Ramos et al. Exercise and protein supplementation for prevention and treatment of sarcopenia
Yoshimatsu et al. Ginsenoside Rg1 prevents histaminergic modulation of rat adaptive behavior from elevation of ambient temperature
Stacher et al. Lack of systematic effects of the 5‐hydroxytryptamine 3 receptor antagonist ICS 205‐930 on gastric emptying and antral motor activity in patients with primary anorexia nervosa.
Tatlici et al. The Effects of Beetroot Juice Supplementation on Balance Performance of Wrestlers
US20210177785A1 (en) Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (hmb) for enhancing recovery from soft tissue trauma
Petrofsky et al. Synergistic effects of continuous low level heat wraps and vitamins in improving balance and gait in adults

Legal Events

Date Code Title Description
FB34 Technical and formal requirements: requirement - article 34 of industrial property law
FA14 Dismissal: dismissal - article 34 of industrial property law
FA10 Dismissal: dismissal - article 33 of industrial property law

Owner name: CERTIFICADO DE ADICAO DE INVENCAO

B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: CERTIFICADO DE ADICAO DE INVENCAO

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: CERTIFICADO DE ADICAO DE INVENCAO

B11T Dismissal of application maintained [chapter 11.20 patent gazette]